JP2023529485A - Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法 - Google Patents

Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法 Download PDF

Info

Publication number
JP2023529485A
JP2023529485A JP2022576447A JP2022576447A JP2023529485A JP 2023529485 A JP2023529485 A JP 2023529485A JP 2022576447 A JP2022576447 A JP 2022576447A JP 2022576447 A JP2022576447 A JP 2022576447A JP 2023529485 A JP2023529485 A JP 2023529485A
Authority
JP
Japan
Prior art keywords
subject
cancer
selectin
groups
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529485A5 (enExample
Inventor
ジョン エル． マグナニ，
ウィリアム イー． フォグラー，
セオドア スミス，
Original Assignee
グリコミメティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリコミメティクス， インコーポレイテッド filed Critical グリコミメティクス， インコーポレイテッド
Publication of JP2023529485A publication Critical patent/JP2023529485A/ja
Publication of JP2023529485A5 publication Critical patent/JP2023529485A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022576447A 2020-06-14 2021-06-11 Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法 Pending JP2023529485A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063038856P 2020-06-14 2020-06-14
US63/038,856 2020-06-14
US202063060605P 2020-08-03 2020-08-03
US63/060,605 2020-08-03
US202063198856P 2020-11-17 2020-11-17
US63/198,856 2020-11-17
PCT/US2021/036992 WO2021257398A1 (en) 2020-06-14 2021-06-11 Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting

Publications (2)

Publication Number Publication Date
JP2023529485A true JP2023529485A (ja) 2023-07-10
JP2023529485A5 JP2023529485A5 (enExample) 2024-06-06

Family

ID=76731129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576447A Pending JP2023529485A (ja) 2020-06-14 2021-06-11 Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法

Country Status (12)

Country Link
US (1) US20230218649A1 (enExample)
EP (1) EP4164655A1 (enExample)
JP (1) JP2023529485A (enExample)
KR (1) KR20230024402A (enExample)
CN (1) CN116033907A (enExample)
AU (1) AU2021292458A1 (enExample)
BR (1) BR112022025480A2 (enExample)
CA (1) CA3181278A1 (enExample)
IL (1) IL298977A (enExample)
MX (1) MX2022015894A (enExample)
WO (1) WO2021257398A1 (enExample)
ZA (1) ZA202213322B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250100273A (ko) * 2023-12-26 2025-07-03 서울대학교병원 난소암 예방 또는 치료를 위한 데시타빈 및 벨로테칸의 병용 요법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096926A1 (en) * 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
WO2019108750A1 (en) * 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
WO2019173229A1 (en) * 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2264043T3 (pl) 2005-09-02 2018-04-30 Glycomimetics, Inc. Heterobifunkcyjne inhibitory pan-selektyny
WO2009073911A1 (en) 2007-12-10 2009-06-18 Mater Medical Research Institute Treatment and prophylaxis
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
WO2015048616A1 (en) * 2013-09-30 2015-04-02 Glycomimetics, Inc. Methods and compositions for treating and/or preventing mucositis
JP6689854B2 (ja) 2014-12-03 2020-04-28 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US20200171005A9 (en) 2015-12-02 2020-06-04 Glycomimetics, Inc. Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker
AU2017341065B2 (en) 2016-10-07 2023-04-06 Crescent Biopharma, Inc. Highly potent multimeric E-selectin antagonists
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
WO2020219419A1 (en) 2019-04-24 2020-10-29 Glycomimetics, Inc. Multimeric pan–selectin antagonists
JP2022529806A (ja) 2019-04-24 2022-06-24 グリコミメティクス， インコーポレイテッド Ｅ－セレクチン、ガレクチン－３、および／またはｃｘｃｒ４ケモカイン受容体のガラクトース連結型多量体糖模倣性阻害剤
US20220265691A1 (en) 2019-07-12 2022-08-25 Glycomimetics, Inc. Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013096926A1 (en) * 2011-12-22 2013-06-27 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
WO2019108750A1 (en) * 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
WO2019173229A1 (en) * 2018-03-05 2019-09-12 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER TREATMENT REVIEWS,, vol. 75, JPN6025027104, 2019, pages 52 - 61, ISSN: 0005763276 *

Also Published As

Publication number Publication date
WO2021257398A1 (en) 2021-12-23
CN116033907A (zh) 2023-04-28
CA3181278A1 (en) 2021-12-23
EP4164655A1 (en) 2023-04-19
BR112022025480A2 (pt) 2023-01-17
MX2022015894A (es) 2023-01-24
ZA202213322B (en) 2024-04-24
KR20230024402A (ko) 2023-02-20
AU2021292458A1 (en) 2023-01-19
US20230218649A1 (en) 2023-07-13
IL298977A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
Yoshimura et al. The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis
ES2974678T3 (es) Uso del anticuerpo anti CD70 ARGX-110 para tratar la leucemia mieloide aguda
RU2768186C2 (ru) Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1
EP2249854A1 (en) Improved treatment and prophylaxis
WO2011069141A2 (en) Interferon therapies in combination with blockade of stat3 activation
Xia et al. Angiogenic factors in chronic lymphocytic leukemia
Huang et al. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia
Jaina et al. Anti-cancer activity of Biochanin A against multiple myeloma by targeting the CD38 and cancer stem-like cells
US20110195924A1 (en) Methods of Inhibiting the Interaction Between S100P and the Receptor for Advanced Glycation End-Products
Deng et al. Narciclasine induces colon carcinoma cell apoptosis by inhibiting the IL-17A/Act1/TRAF6/NF-κB signaling pathway
JP2023529485A (ja) Ｅ－セレクチン標的化を介して微小環境媒介耐性を克服するための組成物および方法
EP3731853A1 (en) Method for treating breast cancer and chronic diseases
WO2021011435A1 (en) Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types
US20240269157A1 (en) Compositions and methods for overcoming microenvironment-mediated resistance via e-selectin targeting
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
WO2011088402A2 (en) The use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
JP2023527411A (ja) がん細胞の負荷を減少させ、正常な造血を保護するための化合物および方法
CN115282280A (zh) TGF-β1信号抑制剂的新用途
US9351981B2 (en) Use of PKC-iota inhibitors for the treatment of breast cancer
KR20230044452A (ko) 암을 치료하기 위한 bcl-2 억제제 및 저메틸화제의 조합물, 이의 용도 및 약학적 조성물
KR102558989B1 (ko) 항암 화학요법으로 인한 내성을 완화하고 항암 화학요법의 효과를 증진시키기 위한 약학적 조성물 및 그 용도
WO2026064898A1 (en) Combination therapies
Garrido et al. The anti-tumor activity of the 7A7 antibody, specific to murine EGFR, is independent of target expression levels in immunocompetent mice
Podolski et al. INFLUENCE OF TREATMENT WITH AREDIA (PAMIDRO-NAT ON THE SKELETAL METASTASES FROM BREAST CANCER
BEDSIDE Presidential Symposium

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260105